Bank Of Montreal Ligand Pharmaceuticals Inc Transaction History

Bank Of Montreal

$201 Billion
Q2 2025

A detailed history of Bank Of Montreal transactions in Ligand Pharmaceuticals Inc stock. As of the latest transaction made, Bank Of Montreal holds 5,726 shares of LGND stock, worth $1.03 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

5,726

Previous 5,579 2.63%

Holding current value

$1.03 Million

Previous $586,000 10.92%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 05, 2025	BUY	$96.67 - $118.22 $14,210 - $17,378	147 Added 2.63%	5,726 $650,000
Q1 2025 May 13, 2025	BUY	$105.14 - $122.23 $103,142 - $119,907	981 Added 21.34%	5,579 $586,000
Q4 2024 Feb 13, 2025	BUY	$99.95 - $129.9 $22,588 - $29,357	226 Added 5.17%	4,598 $492,000
Q3 2024 Nov 13, 2024	BUY	$82.7 - $110.11 $12,405 - $16,516	150 Added 3.55%	4,372 $437,000
Q2 2024 Aug 14, 2024	BUY	$68.53 - $87.91 $5,550 - $7,120	81 Added 1.96%	4,222 $355,000
Q1 2024 May 13, 2024	BUY	$68.64 - $89.2 $13,178 - $17,126	192 Added 4.86%	4,141 $302,000
Q4 2023 Feb 08, 2024	BUY	$49.57 - $72.63 $195,751 - $286,815	3,949 New	3,949 $282,000
Q2 2022 Aug 11, 2022	SELL	$74.52 - $117.06 $333,327 - $523,609	-4,473 Closed	0 $0
Q1 2022 May 12, 2022	SELL	$94.99 - $151.56 $7,409 - $11,821	-78 Reduced 1.71%	4,473 $540,000
Q4 2021 Feb 11, 2022	SELL	$127.69 - $165.85 $160,761 - $208,805	-1,259 Reduced 21.67%	4,551 $741,000
Q3 2021 Nov 12, 2021	BUY	$102.33 - $144.73 $454,345 - $642,601	4,440 Added 324.09%	5,810 $821,000
Q2 2021 Aug 12, 2021	BUY	$113.03 - $155.64 $154,851 - $213,226	1,370 New	1,370 $190,000

Others Institutions Holding LGND

# of Institutions

290

Shares Held

19.5M

Call Options Held

Put Options Held

View Full List

About LIGAND PHARMACEUTICALS INC

Ticker LGND
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 16,882,800
Market Cap $3.04B
Description
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...

More about LGND

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of Montreal , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of Montreal with notifications on news.

Account